SAB Biotherapeutics, Inc. (SABS) is a Biotechnology company in the Healthcare sector, currently trading at $3.86. It has a SharesGrow Score of 54/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of SABS = $5.59 (+44.8% from the current price, the stock appears undervalued). Analyst consensus target is SABS = $7 (+81.3% upside).
Valuation: SABS trades at a trailing Price-to-Earnings (P/E) of 5.4 (S&P 500 average ~25).
Net income is $13M, growing at +11%/yr. Net profit margin is 0% (thin). Gross margin is -262.5% (-348.7 pp trend).
Balance sheet: total debt is $6M against $151M equity (Debt-to-Equity (D/E) ratio 0.04, conservative). Current ratio is 9.46 (strong liquidity). Debt-to-assets is 3.4%. Total assets: $173M.
Analyst outlook: 5 / 6 analysts rate SABS as buy (83%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 48/100 (Partial), Past 25/100 (Fail), Health 67/100 (Partial), Moat 0/100 (Fail), Future 94/100 (Pass), Income ?/100 (Fail).
